A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies

D. E. Brenner, C. Garbino, H. Kasdorf, U. Villasanta, R. Polcaro, J. Yovarone, Joseph Aisner, C. A. Schiffer, P. H. Wiernik

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Thirty-two patients with advanced gynecologic malignancies were treated with m-AMSA, 120 mg/m2 intravenously every 3 weeks. Seventeen patients with advanced carcinoma of the cervix who were treated with m-AMSA had a median performance status (CALGB scale) of 2. There were two partial responses (PR) (14%) in 16 evaluable patients. The median duration of survival was 76 days following the initiation of m-AMSA treatment. In ovarian carcinoma, none of the nine evaluable patients who were treated responded. One PR occurred among four treated patients with endometrial adeno-carcinoma. Toxicity was limited to myelosuppression (WBC<2500/μl in 29/77 courses, WBC<1500/μl in 16/77 courses, platelets<100,000/μl in 10/77 courses, and drug-induced anemia in 7/77 courses) and mild to moderate nausea and vomiting (10/31 patients). Three patients required hospitalization for fever and granulocytopenia, and one patient died from drug-induced sepsis. Although toxicity was acceptable in this group of heavily pretreated patients, m-AMSA has limited activity in patients with advanced carcinoma of the cervix and no apparent activity in patients with advanced epithelial ovarian carcinomas. Continued trials are indicated in patients with adenocarcinoma of the endometrium.

Original languageEnglish (US)
Pages (from-to)291-295
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number3
StatePublished - Dec 1 1982
Externally publishedYes

Fingerprint

Amsacrine
Neoplasms
Therapeutics
Carcinoma
Cervix Uteri
Agranulocytosis
Endometrial Neoplasms
Endometrium
Pharmaceutical Preparations
Nausea
Vomiting

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Brenner, D. E., Garbino, C., Kasdorf, H., Villasanta, U., Polcaro, R., Yovarone, J., ... Wiernik, P. H. (1982). A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 5(3), 291-295.
Brenner, D. E. ; Garbino, C. ; Kasdorf, H. ; Villasanta, U. ; Polcaro, R. ; Yovarone, J. ; Aisner, Joseph ; Schiffer, C. A. ; Wiernik, P. H. / A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1982 ; Vol. 5, No. 3. pp. 291-295.
@article{a9896ef532464ff8b862f89b77730da1,
title = "A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies",
abstract = "Thirty-two patients with advanced gynecologic malignancies were treated with m-AMSA, 120 mg/m2 intravenously every 3 weeks. Seventeen patients with advanced carcinoma of the cervix who were treated with m-AMSA had a median performance status (CALGB scale) of 2. There were two partial responses (PR) (14{\%}) in 16 evaluable patients. The median duration of survival was 76 days following the initiation of m-AMSA treatment. In ovarian carcinoma, none of the nine evaluable patients who were treated responded. One PR occurred among four treated patients with endometrial adeno-carcinoma. Toxicity was limited to myelosuppression (WBC<2500/μl in 29/77 courses, WBC<1500/μl in 16/77 courses, platelets<100,000/μl in 10/77 courses, and drug-induced anemia in 7/77 courses) and mild to moderate nausea and vomiting (10/31 patients). Three patients required hospitalization for fever and granulocytopenia, and one patient died from drug-induced sepsis. Although toxicity was acceptable in this group of heavily pretreated patients, m-AMSA has limited activity in patients with advanced carcinoma of the cervix and no apparent activity in patients with advanced epithelial ovarian carcinomas. Continued trials are indicated in patients with adenocarcinoma of the endometrium.",
author = "Brenner, {D. E.} and C. Garbino and H. Kasdorf and U. Villasanta and R. Polcaro and J. Yovarone and Joseph Aisner and Schiffer, {C. A.} and Wiernik, {P. H.}",
year = "1982",
month = "12",
day = "1",
language = "English (US)",
volume = "5",
pages = "291--295",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Brenner, DE, Garbino, C, Kasdorf, H, Villasanta, U, Polcaro, R, Yovarone, J, Aisner, J, Schiffer, CA & Wiernik, PH 1982, 'A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 5, no. 3, pp. 291-295.

A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. / Brenner, D. E.; Garbino, C.; Kasdorf, H.; Villasanta, U.; Polcaro, R.; Yovarone, J.; Aisner, Joseph; Schiffer, C. A.; Wiernik, P. H.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 5, No. 3, 01.12.1982, p. 291-295.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies

AU - Brenner, D. E.

AU - Garbino, C.

AU - Kasdorf, H.

AU - Villasanta, U.

AU - Polcaro, R.

AU - Yovarone, J.

AU - Aisner, Joseph

AU - Schiffer, C. A.

AU - Wiernik, P. H.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - Thirty-two patients with advanced gynecologic malignancies were treated with m-AMSA, 120 mg/m2 intravenously every 3 weeks. Seventeen patients with advanced carcinoma of the cervix who were treated with m-AMSA had a median performance status (CALGB scale) of 2. There were two partial responses (PR) (14%) in 16 evaluable patients. The median duration of survival was 76 days following the initiation of m-AMSA treatment. In ovarian carcinoma, none of the nine evaluable patients who were treated responded. One PR occurred among four treated patients with endometrial adeno-carcinoma. Toxicity was limited to myelosuppression (WBC<2500/μl in 29/77 courses, WBC<1500/μl in 16/77 courses, platelets<100,000/μl in 10/77 courses, and drug-induced anemia in 7/77 courses) and mild to moderate nausea and vomiting (10/31 patients). Three patients required hospitalization for fever and granulocytopenia, and one patient died from drug-induced sepsis. Although toxicity was acceptable in this group of heavily pretreated patients, m-AMSA has limited activity in patients with advanced carcinoma of the cervix and no apparent activity in patients with advanced epithelial ovarian carcinomas. Continued trials are indicated in patients with adenocarcinoma of the endometrium.

AB - Thirty-two patients with advanced gynecologic malignancies were treated with m-AMSA, 120 mg/m2 intravenously every 3 weeks. Seventeen patients with advanced carcinoma of the cervix who were treated with m-AMSA had a median performance status (CALGB scale) of 2. There were two partial responses (PR) (14%) in 16 evaluable patients. The median duration of survival was 76 days following the initiation of m-AMSA treatment. In ovarian carcinoma, none of the nine evaluable patients who were treated responded. One PR occurred among four treated patients with endometrial adeno-carcinoma. Toxicity was limited to myelosuppression (WBC<2500/μl in 29/77 courses, WBC<1500/μl in 16/77 courses, platelets<100,000/μl in 10/77 courses, and drug-induced anemia in 7/77 courses) and mild to moderate nausea and vomiting (10/31 patients). Three patients required hospitalization for fever and granulocytopenia, and one patient died from drug-induced sepsis. Although toxicity was acceptable in this group of heavily pretreated patients, m-AMSA has limited activity in patients with advanced carcinoma of the cervix and no apparent activity in patients with advanced epithelial ovarian carcinomas. Continued trials are indicated in patients with adenocarcinoma of the endometrium.

UR - http://www.scopus.com/inward/record.url?scp=0020317417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020317417&partnerID=8YFLogxK

M3 - Article

C2 - 6896260

AN - SCOPUS:0020317417

VL - 5

SP - 291

EP - 295

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -

Brenner DE, Garbino C, Kasdorf H, Villasanta U, Polcaro R, Yovarone J et al. A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials. 1982 Dec 1;5(3):291-295.